Fibrocell Science Inc (NASDAQ:FCSC) Short Interest Down 9.8% in October

Fibrocell Science Inc (NASDAQ:FCSC) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 234,800 shares, a decline of 9.8% from the September 30th total of 260,200 shares. Based on an average daily volume of 138,500 shares, the days-to-cover ratio is currently 1.7 days. Approximately 3.2% of the company’s stock are short sold.

Shares of NASDAQ FCSC traded up $0.01 during trading on Friday, hitting $2.99. The stock had a trading volume of 52,300 shares, compared to its average volume of 27,767. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.50 and a quick ratio of 3.50. The firm has a fifty day moving average of $2.97 and a two-hundred day moving average of $2.25. The company has a market capitalization of $29.08 million, a PE ratio of -2.06 and a beta of 1.67. Fibrocell Science has a 12 month low of $1.45 and a 12 month high of $3.28.

Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $1.30. The company had revenue of $21.79 million during the quarter. On average, equities analysts expect that Fibrocell Science will post 0.1 earnings per share for the current fiscal year.

A number of analysts have commented on the stock. Canaccord Genuity lowered shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research note on Monday, September 16th. ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research upgraded shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Wednesday. Finally, HC Wainwright lowered shares of Fibrocell Science from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Friday, September 13th.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley grew its position in Fibrocell Science by 13.2% during the second quarter. Morgan Stanley now owns 59,900 shares of the company’s stock valued at $114,000 after acquiring an additional 7,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Fibrocell Science by 140.6% in the second quarter. Vanguard Group Inc. now owns 394,456 shares of the company’s stock worth $749,000 after purchasing an additional 230,522 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Fibrocell Science by 38.0% in the second quarter. Renaissance Technologies LLC now owns 740,454 shares of the company’s stock worth $1,407,000 after purchasing an additional 204,015 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Fibrocell Science in the second quarter worth approximately $71,000. Institutional investors and hedge funds own 32.92% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Further Reading: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit